Piramal Snaps Up Peptide API Specialist Hemmo
Bolsters CDMO Business In Deal Worth More Than $100m
Executive Summary
Piramal has announced a $106m deal to take full ownership of peptide API specialist Hemmo Pharmaceuticals, expanding its CDMO capabilities.